Company Profile

ESTABLISHED IN 1986, IND-SWIFT IS A RESEARCH DRIVEN PHARMACEUTICAL GROUP KNOWN FOR WORLD CLASS FINISHED DOSAGE FORMS, ACTIVE PHARMACEUTICAL INGREDIENTS, AND INTERMEDIATES. THE GROUP SEES ITSELF AS A STAKEHOLDER IN THE SERVICE TO HUMANITY, OFFERING QUALITY PHARMACEUTICALS THAT MITIGATE ILLNESS AND SUFFERING, AND CONTRIBUTE TO A HEALTHIER AND BETTER WORLD. IND-SWIFT IS A PUBLIC LIMITED COMPANY LISTED ON THE BOMBAY STOCK EXCHANGE AND NATIONAL STOCK EXCHANGE. IND SWIFT LIMITED-GLOBAL BUSINESS UNIT (ISL-GBU) WAS COMMISSIONED IN 2006, TO CATER EXCLUSIVELY TO THE DEMAND OF THE INTERNATIONAL MARKETS FOR FINISHED DOSAGE FORMS. PRODUCTS FROM GBU ARE NOW AVAILABLE IN MANY COUNTRIES OF EU, AUSTRALIA, CANADA, CENTRAL & LATIN AMERICA, ASIA, RUSSIA & CIS AND AFRICA-INCLUDING SOUTH AFRICA. ISL-GBU IS APPROVED BY MHRA, TGA, HEALTH CANADA, WHO-GMP & OTHER LEADING REGULATORY AGENCIES FOR TABLETS, HARD GELATIN CAPSULES AND DRY POWDER-SACHET. ISL-GBU IS ONE OF THE FEW FACILITIES THAT CAN PROVIDE SPECIFIC